279 related articles for article (PubMed ID: 10699946)
21. Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer.
Dickler MN; Ragupathi G; Liu NX; Musselli C; Martino DJ; Miller VA; Kris MG; Brezicka FT; Livingston PO; Grant SC
Clin Cancer Res; 1999 Oct; 5(10):2773-9. PubMed ID: 10537341
[TBL] [Abstract][Full Text] [Related]
22. Vaccination with a bivalent G(M2) and G(D2) ganglioside conjugate vaccine: a trial comparing doses of G(D2)-keyhole limpet hemocyanin.
Chapman PB; Morrisey D; Panageas KS; Williams L; Lewis JJ; Israel RJ; Hamilton WB; Livingston PO
Clin Cancer Res; 2000 Dec; 6(12):4658-62. PubMed ID: 11156217
[TBL] [Abstract][Full Text] [Related]
23. The immune response to disialoganglioside GD3 vaccination in normal dogs: a melanoma surface antigen vaccine.
Milner RJ; Salute M; Crawford C; Abbot JR; Farese J
Vet Immunol Immunopathol; 2006 Dec; 114(3-4):273-84. PubMed ID: 17027091
[TBL] [Abstract][Full Text] [Related]
24. Constructing an adenocarcinoma vaccine: immunization of mice with synthetic KH-1 nonasaccharide stimulates anti-KH-1 and anti-Le(y) antibodies.
Ragupathi G; Deshpande PP; Coltart DM; Kim HM; Williams LJ; Danishefsky SJ; Livingston PO
Int J Cancer; 2002 May; 99(2):207-12. PubMed ID: 11979435
[TBL] [Abstract][Full Text] [Related]
25. Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer.
Sabbatini PJ; Ragupathi G; Hood C; Aghajanian CA; Juretzka M; Iasonos A; Hensley ML; Spassova MK; Ouerfelli O; Spriggs DR; Tew WP; Konner J; Clausen H; Abu Rustum N; Dansihefsky SJ; Livingston PO
Clin Cancer Res; 2007 Jul; 13(14):4170-7. PubMed ID: 17634545
[TBL] [Abstract][Full Text] [Related]
26. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.
Livingston PO; Natoli EJ; Calves MJ; Stockert E; Oettgen HF; Old LJ
Proc Natl Acad Sci U S A; 1987 May; 84(9):2911-5. PubMed ID: 3472242
[TBL] [Abstract][Full Text] [Related]
27. Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21.
Gilewski TA; Ragupathi G; Dickler M; Powell S; Bhuta S; Panageas K; Koganty RR; Chin-Eng J; Hudis C; Norton L; Houghton AN; Livingston PO
Clin Cancer Res; 2007 May; 13(10):2977-85. PubMed ID: 17504999
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial.
Eggermont AM; Suciu S; Rutkowski P; Marsden J; Santinami M; Corrie P; Aamdal S; Ascierto PA; Patel PM; Kruit WH; Bastholt L; Borgognoni L; Bernengo MG; Davidson N; Polders L; Praet M; Spatz A
J Clin Oncol; 2013 Oct; 31(30):3831-7. PubMed ID: 24019551
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of widely consumed botanicals as immunological adjuvants.
Ragupathi G; Yeung KS; Leung PC; Lee M; Lau CB; Vickers A; Hood C; Deng G; Cheung NK; Cassileth B; Livingston P
Vaccine; 2008 Sep; 26(37):4860-5. PubMed ID: 18640165
[TBL] [Abstract][Full Text] [Related]
30. Immunization with N-propionyl polysialic acid-KLH conjugate in patients with small cell lung cancer is safe and induces IgM antibodies reactive with SCLC cells and bactericidal against group B meningococci.
Krug LM; Ragupathi G; Hood C; George C; Hong F; Shen R; Abrey L; Jennings HJ; Kris MG; Livingston PO
Cancer Immunol Immunother; 2012 Jan; 61(1):9-18. PubMed ID: 21811785
[TBL] [Abstract][Full Text] [Related]
31. Analysis of the antibody response to immunization with purified O-acetyl GD3 gangliosides in patients with malignant melanoma.
Ritter G; Ritter-Boosfeld E; Adluri R; Calves M; Ren S; Yu RK; Oettgen HF; Old LJ; Livingston PO
Int J Cancer; 1995 Sep; 62(6):668-72. PubMed ID: 7558412
[TBL] [Abstract][Full Text] [Related]
32. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21.
Gilewski T; Adluri S; Ragupathi G; Zhang S; Yao TJ; Panageas K; Moynahan M; Houghton A; Norton L; Livingston PO
Clin Cancer Res; 2000 May; 6(5):1693-701. PubMed ID: 10815887
[TBL] [Abstract][Full Text] [Related]
33. Antibody response to immunization with ganglioside GD3 and GD3 congeners (lactones, amide and gangliosidol) in patients with malignant melanoma.
Ritter G; Boosfeld E; Adluri R; Calves M; Oettgen HF; Old LJ; Livingston P
Int J Cancer; 1991 May; 48(3):379-85. PubMed ID: 2040532
[TBL] [Abstract][Full Text] [Related]
34. Keyhole limpet hemocyanin conjugate vaccines against cancer: the Memorial Sloan Kettering experience.
Musselli C; Livingston PO; Ragupathi G
J Cancer Res Clin Oncol; 2001 Oct; 127 Suppl 2():R20-6. PubMed ID: 11768620
[TBL] [Abstract][Full Text] [Related]
35. Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma.
Livingston PO; Adluri S; Helling F; Yao TJ; Kensil CR; Newman MJ; Marciani D
Vaccine; 1994 Nov; 12(14):1275-80. PubMed ID: 7856291
[TBL] [Abstract][Full Text] [Related]
36. A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: a study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 OR QS-21.
Slovin SF; Ragupathi G; Fernandez C; Jefferson MP; Diani M; Wilton AS; Powell S; Spassova M; Reis C; Clausen H; Danishefsky S; Livingston P; Scher HI
Vaccine; 2005 May; 23(24):3114-22. PubMed ID: 15837210
[TBL] [Abstract][Full Text] [Related]
37. Synthesis of sialyl Lewis(a) (sLe (a), CA19-9) and construction of an immunogenic sLe(a) vaccine.
Ragupathi G; Damani P; Srivastava G; Srivastava O; Sucheck SJ; Ichikawa Y; Livingston PO
Cancer Immunol Immunother; 2009 Sep; 58(9):1397-405. PubMed ID: 19190907
[TBL] [Abstract][Full Text] [Related]
38. GD3/proteosome vaccines induce consistent IgM antibodies against the ganglioside GD3.
Livingston PO; Calves MJ; Helling F; Zollinger WD; Blake MS; Lowell GH
Vaccine; 1993 Sep; 11(12):1199-204. PubMed ID: 8256501
[TBL] [Abstract][Full Text] [Related]
39. Immunization of mice with fucosyl-GM1 conjugated with keyhole limpet hemocyanin results in antibodies against human small-cell lung cancer cells.
Cappello S; Liu NX; Musselli C; Brezicka FT; Livingston PO; Ragupathi G
Cancer Immunol Immunother; 1999 Dec; 48(9):483-92. PubMed ID: 10602885
[TBL] [Abstract][Full Text] [Related]
40. Bioengineering of surface GD3 ganglioside for immunotargeting human melanoma cells.
Zou W; Borrelli S; Gilbert M; Liu T; Pon RA; Jennings HJ
J Biol Chem; 2004 Jun; 279(24):25390-9. PubMed ID: 15047693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]